secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADC Therapeutics SA (ADCT)
CIK:        0001771910
Form:       8-K
Filed at:   2026-08-13T13:14:34+00:00
Accession:  0000950103-26-012287
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADC Therapeutics Q2 revenue $18.6M; FDA flags LOTIS-5 benefit-risk concerns
---------------------------------------------------------------------------

- Q2 net product revenue $18.6M vs $18.1M YoY; six-month revenue $38.7M vs $35.5M.
- Q2 net loss $16.6M ($0.11/share) vs $56.6M loss in 2025; adjusted net loss $16.3M.
- Cash $219.1M at June 30, 2026; runway at least into 2028.
- FDA pre-sBLA meeting cited Grade 5 event imbalance and marginal benefit; regulatory path under review.
- 17% workforce cut yields ~$10M annual savings; LOTIS-7 enrollment complete at 100 patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1771910/000095010326012287/0000950103-26-012287-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1771910/000095010326012287/dp251718_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-26-012287

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer